

# Person—glycosylated haemoglobin level (measured), percentage N[N].N

Exported from METEOR (AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at <https://creativecommons.org/licenses/by/4.0/>.

Enquiries relating to copyright should be addressed to [info@aihw.gov.au](mailto:info@aihw.gov.au).

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at [meteor@aihw.gov.au](mailto:meteor@aihw.gov.au).

# Person—glycosylated haemoglobin level (measured), percentage N[N].N

## Identifying and definitional attributes

<b>Metadata item type:</b>	Data Element
<b>Short name:</b>	Glycosylated haemoglobin level (measured)
<b>METEOR identifier:</b>	270325
<b>Registration status:</b>	<a href="#">Health</a> , Standard 01/03/2005
<b>Definition:</b>	A person's glycosylated haemoglobin (HbA1c) level, measured as percentage.
<b>Data Element Concept:</b>	<a href="#">Person—glycosylated haemoglobin level</a>
<b>Value Domain:</b>	<a href="#">Percentage N[N].N</a>

## Value domain attributes

## Representational attributes

<b>Representation class:</b>	Percentage	
<b>Data type:</b>	Number	
<b>Format:</b>	N[N].N	
<b>Maximum character length:</b>	3	
	<b>Value</b>	<b>Meaning</b>
<b>Supplementary values:</b>	99.9	Not stated/inadequately described

## Data element attributes

## Collection and usage attributes


<b>Guide for use:</b>	HbA1c results vary between laboratories; use the same laboratory for repeated testing.  When reporting, record absolute result of the most recent HbA1c level in the last 12 months.  Record the absolute result of the test (%).
<b>Collection methods:</b>	Test is performed in accredited laboratories: <ul style="list-style-type: none"><li>• A single blood sample is sufficient and no preparation of the patient is required.</li><li>• Measure HbA1c ideally using High Performance Liquid Chromatography (HPLC).</li></ul>

## Source and reference attributes

<b>Submitting organisation:</b>	National diabetes data working group
<b>Origin:</b>	National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary.
<b>Reference documents:</b>	Koenig, R. J. Peterson, CM and Kilo, C et al. Hemoglobin A1c as an indicator of the degree of glucose intolerance in diabetes. Diabetes 259 (1976): 230-232. Nathan, D.M., Singer, D.E, Hurxthal, K, and Goodson, J.D. The clinical information value of the glycosylated hemoglobin assay. N. Eng. J. Med. 310 (1984): 341-346.

# Relational attributes

## Related metadata references:

Is re-engineered from  [Glycosylated Haemoglobin \(HbA1c\) - measured, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf](#) (18.0 KB)  
*No registration status*

See also [Laboratory standard—upper limit of normal range of glycosylated haemoglobin, percentage N\[N\].N](#)  
[Health](#), Standard 01/03/2005

## Implementation in Data Set Specifications:

[Acute coronary syndrome \(clinical\) DSS](#)  
[Health](#), Superseded 01/09/2012

[Acute coronary syndrome \(clinical\) DSS](#)  
[Health](#), Superseded 02/05/2013

[Acute coronary syndrome \(clinical\) NBPDS 2013-](#)  
[Health](#), Standard 02/05/2013

**Implementation start date:** 01/07/2013

[Diabetes \(clinical\) DSS](#)  
[Health](#), Superseded 21/09/2005

[Diabetes \(clinical\) NBPDS](#)  
[Health](#), Standard 21/09/2005

### **DSS specific information:**

The HbA1c along with regular blood glucose monitoring is the best way to see the overall picture of blood glucose levels.

HbA1c is a measurement of long-term blood glucose control and is used to assess the effectiveness of treatment. The level of HbA1c is proportional to the level of glucose in the blood over a period of approximately two months, because glucose attaches to the haemoglobin (red blood cells) and remains there for the life of the red blood cell, approximately 120 days. The HbA1c gives an average of the blood glucose level over the past 6-8 weeks and therefore HbA1c is accepted as an indicator of the mean daily blood glucose concentration over the preceding two months.

HbA1c is formed by the non-enzymatic glycation of the N-terminus of the B- chain of haemoglobin Ao. It is a convenient way to obtain an integrated assessment of antecedent glycaemia over an extended period under real life conditions used as a standard for assessing overall blood glucose control.

Research studies in the United States have found that for every 1% reduction in results of HbA1c blood tests, the risk of developing micro vascular diabetic complications (eye, kidney, and nerve disease) is reduced by 40 percent.

The maintenance of good glycaemic control (in diabetes Type 1 and Type 2), significantly reduces progression of diabetes-related complications such as retinopathy, nephropathy and neuropathy, as indicated in the Diabetes Control and Complications Trial (DCCT 1993) and United Kingdom Prospective Diabetes Study (UKPDS 1997).

The target proposed by the Australian Diabetes Society for glycosylated haemoglobin (HbA1c) is 7.0% or less and a doctor may order this test about every 3 - 6 months.